Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
M412829-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $868.90 | |
M412829-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $890.90 | |
M412829-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $121.90 | |
M412829-50mg | 50mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,011.90 | |
M412829-100mg | 100mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,102.90 |
Synonyms | (R)-1-[6-[(R)-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]-pyrrolidine-2-carboxylic acid | 4avt | Spectrum_001388 | N-(3-[(1-Benzylcycloheptyl)oxy]propyl)-N,N-dimethylamine # | CPOHPC acid | D11464 | Rauzide | Phenethylamine, N-(2-hydroxyethyl)-alpha-methyl |
---|---|
Specifications & Purity | Moligand™, ≥97% |
Biochemical and Physiological Mechanisms | Miridesap (CPHPC, Ro63-8695, GSK2315698) is a ligand for serum amyloid P component (SAP) and intends to inhibit and dissociate SAP binding to amyloid fibrils and tangles. CPHPC (Miridesap; Ro 63-8695) is an orally active serum amyloid P (SAP) blocker that |
Storage Temp | Store at -20°C,Argon charged |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | CROSS-LINKING AGENT, INHIBITOR |
Mechanism of action | Serum amyloid P-component cross-linking agent |
Product Description | Information Miridesap (CPHPC, Ro63-8695, GSK2315698) is a ligand for serum amyloid P component (SAP) and intends to inhibit and dissociate SAP binding to amyloid fibrils and tangles. |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
IUPAC Name | (2R)-1-[6-[(2R)-2-carboxypyrrolidin-1-yl]-6-oxohexanoyl]pyrrolidine-2-carboxylic acid |
---|---|
INCHI | InChI=1S/C16H24N2O6/c19-13(17-9-3-5-11(17)15(21)22)7-1-2-8-14(20)18-10-4-6-12(18)16(23)24/h11-12H,1-10H2,(H,21,22)(H,23,24)/t11-,12-/m1/s1 |
InChi Key | HZLAWYIBLZNRFZ-VXGBXAGGSA-N |
Canonical SMILES | C1CC(N(C1)C(=O)CCCCC(=O)N2CCCC2C(=O)O)C(=O)O |
Isomeric SMILES | C1C[C@@H](N(C1)C(=O)CCCCC(=O)N2CCC[C@@H]2C(=O)O)C(=O)O |
PubChem CID | 125516 |
Molecular Weight | 340.37 |
PubChem CID | 125516 |
---|---|
CAS Registry No. | 224624-80-0 |
ChEMBL Ligand | CHEMBL25263 |
Wikipedia | CPHPC |
RCSB PDB Ligand | GHE |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
A2422070 | Certificate of Analysis | Dec 19, 2023 | M412829 |
A2422071 | Certificate of Analysis | Dec 19, 2023 | M412829 |
A2422072 | Certificate of Analysis | Dec 19, 2023 | M412829 |
A2422073 | Certificate of Analysis | Dec 19, 2023 | M412829 |
A2422074 | Certificate of Analysis | Dec 19, 2023 | M412829 |
A2422075 | Certificate of Analysis | Dec 19, 2023 | M412829 |
A2422076 | Certificate of Analysis | Dec 19, 2023 | M412829 |
A2422077 | Certificate of Analysis | Dec 19, 2023 | M412829 |
A2422078 | Certificate of Analysis | Dec 19, 2023 | M412829 |
A2422079 | Certificate of Analysis | Dec 19, 2023 | M412829 |
Pictogram(s) | GHS05 |
---|---|
Signal | Danger |
Hazard Statements | H314:Causes severe skin burns and eye damage H318:Causes serious eye damage |
Precautionary Statements | P280:Wear protective gloves/protective clothing/eye protection/face protection. P321:Specific treatment (see ... on this label). P405:Store locked up. P501:Dispose of contents/container to ... P264:Wash hands [and …] thoroughly after handling. P260:Do not breathe dust/fume/gas/mist/vapors/spray. P301+P330+P331:IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. P304+P340:IF INHALED: Remove person to fresh air and keep comfortable for breathing. P363:Wash contaminated clothing before reuse. P264+P265:Wash hands [and …] thoroughly after handling. Do not touch eyes. P305+P354+P338:IF IN EYES: Immediately rinse with water for several minutes. Remove contact lenses if present and easy to do. Continue rinsing. P317:Get emergency medical help. P302+P361+P354:IF ON SKIN: Take off Immediately all contaminated clothing. Immediately rinse with water for several minutes. P316:Get emergency medical help immediately. |
1. Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C et al.. (2002) Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis.. Nature, 417 (6886): (254-9). [PMID:12015594] [10.1021/op500134e] |
2. Wermuth CG. (2004) Selective optimization of side activities: another way for drug discovery.. J Med Chem, 47 (6): (1303-14). [PMID:14998318] [10.1021/op500134e] |
3. Kolstoe SE, Ridha BH, Bellotti V, Wang N, Robinson CV, Crutch SJ, Keir G, Kukkastenvehmas R, Gallimore JR, Hutchinson WL et al.. (2009) Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component.. Proc Natl Acad Sci USA, 106 (18): (7619-23). [PMID:19372378] [10.1021/op500134e] |
4. Gillmore JD, Tennent GA, Hutchinson WL, Gallimore JR, Lachmann HJ, Goodman HJ, Offer M, Millar DJ, Petrie A, Hawkins PN et al.. (2010) Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis.. Br J Haematol, 148 (5): (760-7). [PMID:20064157] [10.1021/op500134e] |
5. Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA, Hutchinson WL, Mangione PP, Gallimore JR, Millar DJ et al.. (2010) Antibodies to human serum amyloid P component eliminate visceral amyloid deposits.. Nature, 468 (7320): (93-7). [PMID:20962779] [10.1021/op500134e] |